PL3185899T3 - Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd - Google Patents

Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd

Info

Publication number
PL3185899T3
PL3185899T3 PL15817860T PL15817860T PL3185899T3 PL 3185899 T3 PL3185899 T3 PL 3185899T3 PL 15817860 T PL15817860 T PL 15817860T PL 15817860 T PL15817860 T PL 15817860T PL 3185899 T3 PL3185899 T3 PL 3185899T3
Authority
PL
Poland
Prior art keywords
hvt
vectored
improved
ibd vaccine
ibd
Prior art date
Application number
PL15817860T
Other languages
English (en)
Inventor
Iwan Verstegen
Paulus Jacobus Antonius Sondermeijer
Paul Vermeij
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52282550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3185899(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of PL3185899T3 publication Critical patent/PL3185899T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15817860T 2014-12-24 2015-12-23 Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd PL3185899T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14200340 2014-12-24
PCT/EP2015/081121 WO2016102647A1 (en) 2014-12-24 2015-12-23 Improved hvt-vectored nd-ibd vaccine
EP15817860.8A EP3185899B1 (en) 2014-12-24 2015-12-23 Improved hvt-vectored nd-ibd vaccine

Publications (1)

Publication Number Publication Date
PL3185899T3 true PL3185899T3 (pl) 2018-01-31

Family

ID=52282550

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15817860T PL3185899T3 (pl) 2014-12-24 2015-12-23 Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd

Country Status (12)

Country Link
US (1) US10308956B2 (pl)
EP (1) EP3185899B1 (pl)
JP (1) JP6246985B1 (pl)
CN (1) CN107002097B (pl)
AR (1) AR103245A1 (pl)
BR (1) BR112017013595A2 (pl)
ES (1) ES2648672T3 (pl)
HU (1) HUE035364T2 (pl)
MX (1) MX2017008504A (pl)
PL (1) PL3185899T3 (pl)
RU (1) RU2692013C2 (pl)
WO (1) WO2016102647A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216287A1 (en) 2016-06-17 2017-12-21 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
MA55772A (fr) * 2016-12-14 2022-03-02 Boehringer Ingelheim Animal Health Usa Inc Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN111542599A (zh) * 2017-10-12 2020-08-14 英特维特国际股份有限公司 编码多种异源抗原的重组非致病性马尔克氏病病毒构建体
WO2019121888A1 (en) 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
CN109320594B (zh) * 2018-11-13 2021-09-28 四川大学 一种禽传染性支气管炎和新城疫的病毒样颗粒、制备方法及应用
CN110331135A (zh) * 2019-07-18 2019-10-15 扬州大学 表达基因vii型新城疫病毒融合蛋白的重组火鸡疱疹病毒候选疫苗株及制备方法
CN114616325A (zh) * 2019-09-11 2022-06-10 硕腾服务有限责任公司 表达禽病原体抗原的重组火鸡疱疹病毒载体和其用途
US20230031097A1 (en) 2019-12-20 2023-02-02 Intervet Inc. Multivalent hvt vector vaccine
IL299033A (en) 2020-06-17 2023-02-01 Boehringer Ingelheim Vetmedica Gmbh Recombinant HVT vectors expressing influenza hemagglutinin and immunogenic compounds, production and uses thereof
BR112023004123A2 (pt) 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
CN112501139B (zh) * 2020-12-11 2023-03-21 新乡学院 一株重组新城疫病毒毒株及其制备方法和应用
EP4267179A1 (en) 2020-12-24 2023-11-01 Intervet International B.V. Multivalent hvt vector vaccine
WO2023213946A1 (en) 2022-05-05 2023-11-09 Intervet International B.V. New multivalent hvt vector vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
WO1987004463A1 (en) * 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
GB8603341D0 (en) 1986-02-11 1986-03-19 Portapax Ltd Foam sheet
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
US6632664B1 (en) 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US20110110887A1 (en) 2008-06-23 2011-05-12 Wilhelmus Gerardus Johannes Degen Recombinant herpesvirus of turkeys encoding for interleukin-12
CA3146727C (en) * 2011-10-21 2023-10-31 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
EP2768529A1 (en) * 2011-10-21 2014-08-27 Intervet International B.V. Recombinant nonpathogenic mdv vector providing multivalent immunity
US9114108B2 (en) * 2011-11-30 2015-08-25 Merial, Inc. Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof
ES2719409T5 (es) * 2011-11-30 2022-12-07 Boehringer Ingelheim Animal Health Usa Inc Vectores recombinantes de Gallid herpesvirus 3 (mdv serotipo 2) que expresan antígenos de patógenos aviares y usos de los mismos
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
CN107002044B (zh) 2014-12-04 2020-10-30 英特维特国际股份有限公司 永生化鸡胚成纤维细胞

Also Published As

Publication number Publication date
RU2692013C2 (ru) 2019-06-19
WO2016102647A1 (en) 2016-06-30
RU2017126030A3 (pl) 2019-01-24
MX2017008504A (es) 2017-10-11
CN107002097B (zh) 2021-06-15
ES2648672T3 (es) 2018-01-05
EP3185899A1 (en) 2017-07-05
JP2018501792A (ja) 2018-01-25
BR112017013595A2 (pt) 2018-03-06
JP6246985B1 (ja) 2017-12-13
US10308956B2 (en) 2019-06-04
EP3185899B1 (en) 2017-10-18
AR103245A1 (es) 2017-04-26
CN107002097A (zh) 2017-08-01
HUE035364T2 (en) 2018-05-02
US20170306353A1 (en) 2017-10-26
RU2017126030A (ru) 2019-01-24

Similar Documents

Publication Publication Date Title
GB201410971D0 (en) Vaccine
GB201518684D0 (en) Vaccine
GB201410907D0 (en) No details
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
GB201406608D0 (en) Virus
IL248223B (en) Compositions of vaccine
GB201522132D0 (en) Vaccine
GB201419572D0 (en) Virus
GB201616904D0 (en) Vaccine
RS59406B1 (sr) Poboljšano biovezivo
SI3237612T1 (sl) Variante zaporedja
HK1248560A1 (zh) Dna-肽組合疫苗
PL3188755T3 (pl) Szczepionka
GB201410910D0 (en) No details
GB201402083D0 (en) Retaining means
GB201417214D0 (en) Vaccine
PT3193923T (pt) Adjuvantes
GB2522661B (en) Context configuration
GB201419061D0 (en) Conjugated Vaccine
GB201614387D0 (en) Improved vaccines
GB201603029D0 (en) Vaccine
GB201518917D0 (en) Vaccination
GB201406628D0 (en) Vaccine
GB201503266D0 (en) Vaccination
GB201410184D0 (en) Odontalgic preparation